INTRODUCTION
============

Castleman disease was initially described as a lymphoproliferative disorder causing mediastinal masses characterized by abnormal histopathology.[@r1] Castleman disease has since been subclassified clinically into unicentric (UCD) and multicentric Castleman disease (MCD),[@r2] and subclassified histopathologically into the hyaline-vascular type (HV), plasma-cell type (PC), mixed type, plasmablastic type, and hypervascular type.[@r3] MCD was recently subclassified into human herpes virus-8 (HHV-8)-associated, HHV-8-unassociated (idiopathic MCD \[iMCD\]), POEMS syndrome-associated, and others.[@r3]

A new clinical entity, TAFRO syndrome, characterized by thrombocytopenia, anasarca (edema, pleural effusion, and ascites), fever, reticulin myelofibrosis (or renal insufficiency), and organomegaly (hepatosplenomegaly and lymphadenopathy), was recently described.[@r4] Its diagnostic criteria and disease severity criteria, determined by the All Japan TAFRO Syndrome Research Group in the Research Program for Intractable Diseases of the Ministry of Health, Labour and Welfare (MHLW) of Japan,[@r5] were recently updated (<https://www.facebook.com/CastlemanTAFRO>). As the lymph nodes of individuals with TAFRO syndrome were characterized histopathologically as Castleman disease,[@r6] TAFRO syndrome has been categorized as part of iMCD.

Recently, clinical and basic studies on Castleman disease and TAFRO syndrome were started in Japan and the USA. We collected and analyzed data from more than 200 patients with iMCD, TAFRO syndrome, or conditions mimicking these disorders. Most patients with iMCD exhibit a chronic/indolent clinical course, characterized by polyclonal hypergammopathy, multiple lymphadenopathy, and thrombocytosis. In contrast, most patients with TAFRO syndrome have an acute or sub-acute onset and progressive clinical course, characterized by normal to reduced gammaglobulin levels, thrombocytopenia, small or unnoticeable lymph nodes, and severe pleural effusion, ascites, and anasarca. Lymph node biopsy specimens cannot be obtained from some patients with TAFRO syndrome because of marked bleeding tendency, anasarca, and/or the absence of apparent lymphadenopathy. Although some histological findings may overlap, we speculate that TAFRO syndrome is a distinct clinical entity from typical iMCD.

As there is little epidemiological information on Castleman disease and TAFRO syndrome in Japan, we assumed the epidemiology of these conditions using a fixed-point observation method based on their incidence in Ishikawa prefecture.

PATIENTS AND METHODS
====================

Disease classification
----------------------

The diagnosis of Castleman disease is based on both tentative diagnostic criteria in Japan[@r7] and consensus diagnostic criteria for HHV-8-negative/idiopathic MCD in the USA.[@r3] UCD is defined by the involvement of a single lymph node or by the restriction of affected lymph nodes to a single site, enabling surgical resection. MCD is defined by the involvement of lymph nodes at multiple sites.

The diagnostic criteria for TAFRO syndrome have been previously described.[@r5] Patients with TAFRO syndrome manifesting lymphadenopathy with a Castleman-disease like histology (TAFRO-iMCD) were classified into TAFRO syndrome but not into iMCD.

Epidemiological analysis
------------------------

The incidence of MCD, UCD, and TAFRO syndrome throughout Japan was estimated by a fixed-point observation method based on their incidences in Ishikawa prefecture. This prefecture is located on the coast of the Sea of Japan on the Honshu island, and is relatively rural with few of its 1,140,000 residents moving in or out of this area. This study assumed that most patients in Ishikawa prefecture who developed MCD, UCD, or TAFRO syndrome were seen at 3 major medical centers, i.e., Kanazawa University Hospital, Ishikawa Prefectural Central Hospital, or Kanazawa Medical University Hospital. Patient data were collected from medical records, and this study was approved by the ethics committees of each institute.

The rates of MCD, UCD, and TAFRO syndrome at these three hospitals were discussed among the authors of this paper, and the hematologists and rheumatologists working there, and were estimated to be 60-90%, 35-65%, and 35-65%, respectively. The 10-year survival rates of patients with MCD and UCD were estimated to be 80%[@r8] and 95%,[@r4] respectively, and the 5-year survival rate of patients with TAFRO syndrome was estimated to be 67%. The total numbers of patients with MCD, UCD, or TAFRO syndrome diagnosed at these three hospitals from 2012 through 2018 were collected, and the incidence and prevalence of these conditions were calculated using a fixed-point observation method.

RESULTS
=======

The numbers of diagnosed cases of MCD, UCD, and TAFRO syndrome at the 3 major medical centers in Ishikawa Prefecture were 23, 9, and 8, respectively. In 8 cases of TAFRO syndrome, 7 were TAFRO-iMCD and one lacked lymphadenopathy.

Assuming that the onset follows a Poisson distribution, the annual numbers of individuals in Japan with MCD, UCD, and TAFRO syndrome in Japan were estimated to be 309-731, 71-542, and 110-502, respectively, yielding annual incidence rates per million individuals of 2.4-5.8, 0.6-4.3, and 0.9-4.9, respectively. The prevalence of MCD, UCD, and TAFRO syndrome in Japan was estimated to be 4,180-14,900, 1,350-10,300, and 860-7,240, respectively.

DISCUSSION
==========

Castleman disease can affect patients over a broad age range, from children to the elderly, with median ages of onset being in the 50's for patients with MCD and in the 30's for patients with UCD.[@r8] UCD is reported to be more common in Western countries, China, and South Korea, whereas MCD is more common in Japan.[@r8]^-^[@r10] The Japanese Society of Hematology case registration system of hematological disorders reported that 70% of patients with Castleman disease have MCD, whereas 30% have UCD.[@r11] Most patients with HHV-8-associated MCD are infected with human immunodeficiency virus (HIV).[@r12] More than 80% of MCD patients in a study from France were HHV-8-positive.[@r13] In contrast, HHV-8-associated MCD is markedly rare in Japan.[@r14]^,^[@r15]

Based on data from two US treatment centers, the Fred Hutchinson Cancer Research Center and the Mayo Clinic, the prevalence of Castleman disease in the USA is 0.65-2.37 per million persons.[@r16] Furthermore, a claims database estimated that the incidence of CD was 21-25 per million people, with 23% of these patients thought to have MCD.[@r17] However the reliability of these surveys is questionable due to the 10-fold difference between them.

The Research Group on Castleman Disease formed by the Ministry of Health, Labour and Welfare, Japan estimated that the annual incidence of MCD in Japan is one per 1 million people (120 per year) and the prevalence is 1,500 patients (<http://www.nanbyou.or.jp/entry/5750>) based on data of a multicenter collaborative retrospective study to establish the concept of TAFRO syndrome (UMIN000011809), and by the data of a specific-use survey of tocilizumab (Actemra^R^) by Chugai Pharmaceutical Co., Ltd. (<http://chugai-pharm.jp/hc/ss/pr/drug/act_via0400/report/scs/PDF/20140225_act_epmpv_safe_cd.pdf>).

Over the last decade from 2008 to 2017, the Statistical Research Committee of the Japanese Society of Hematology has registered 320 cases of MCD, 142 of UCD, and 57 of unclassified Castleman disease. These numbers slightly increased over time ([Figure 1](#f1){ref-type="fig"}). In 2017, 73 cases of MCD, 28 of UCD, and two of unclassified Castleman disease were registered. If the capture rate of MCD and UCD in 2017 in this registration period was assumed to be 20-40% and 15-30%, respectively, the annual incidences in Japan would be 183-365 and 83-167, respectively. There was no data for TAFRO syndrome in this survey.

![Annual number of MCD and UCD cases registered by the Statistical Research Committee of the Japanese Society of Hematology. The incidence of these diseases has increased over time.](jslrt-59-175-g001){#f1}

Compared with these prior estimations in Japan, this study using the fixed-point observation method, revealed an at least 2-fold increase in the annual incidence and a 4-fold increase in the prevalence of MCD in Japan. The annual incidences of UCD and MCD estimated by the fixed-point observation method were largely consistent with the estimation using the data of the latest year in the nation-wide registration study conducted by the Japanese Society of Hematology. The number of registered patients with Castleman disease in the registry has slightly increased over time, possibly due to increases in the capture rates rather than increases in the actual incidence. In April 2018, the Ministry of Health, Labour and Welfare included iMCD as one of the designated intractable diseases that may have led to the increase in registered cases by altering its recognition. We also estimated the annual incidence of TAFRO syndrome to be 110-502, which is higher than previously thought.

Although Castleman disease has a long history, it is rare and difficult to diagnose, resulting in underestimation of its incidence and prevalence. Moreover, due to insufficient awareness of TAFRO syndrome, some case may have been misdiagnosed as other diseases.[@r4] The present study suggested that MCD, UCD, and TAFRO syndrome are not as rare as previously assumed in Japan. However, these results are limited in that they were derived from regional data. As the etiologies of these diseases are not fully understood and therapeutic strategies have not been established, especially for TAFRO syndrome, further nationwide clinical and epidemiological studies are warranted.
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